Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

Insights: China Equities outlook

China remains one of the most misunderstood markets in the world, and for value investors, that creates opportunity. The Antipodes China Fund delivered strong returns over the past year, and we believe the conditions for continued outperformance are building.

Portfolio manager John Stavliotis unpacks the themes shaping the portfolio today — from anti-involution and its impact on quality companies like CATL, to China’s renewable energy rollout and the grid infrastructure opportunities it’s creating. 

 

Transcript

Welcome back to another Antipodes Insights video. Today we’ll be focusing on an update on the Antipodes China Fund. I’m joined by John Stavliotis, portfolio manager for the Antipodes China Fund. Welcome, John. Thanks for having me.

Let’s kick things off with a recap of the last 12 months of performance, especially in light of us as a pragmatic value investor. How have we gone?

The China Fund returned 14.5% over the last year, which beat what you would have got from a global index or from Australian indices as measured by MSCI Australia. What was interesting in China was the excessive concentration of returns – only 32.5% of stocks in the index beat the benchmark return, which is the most concentrated level in the last 20 years.

If you look at our positioning, we’ve got exposure to some of the structural winners that benefited from capital flows into the country, and we’ve also got exposure to some of the more cyclical companies that are on extremely depressed valuations because of the weaker growth in the country. Importantly, they’ve shown resilience over the last three years with stable earnings and strong distributions, and we think as the economy recovers these stocks will give us a real outsized return to the portfolio.

Given that positioning, we did underperform the benchmark over the last year, but we are seeing returns broaden and we have generated outperformance in the last 6 months. We believe that if we continue to see this broadening of market returns, we are positioned to benefit from both those structural winners and a recovery in the economy.

In 2025, one of the Chinese central government’s hallmark policies was the concept of anti-involution. Can you explain to the audience what that is all about and how we try to exploit it through the portfolio?

Anti-involution is effectively anti-excessive competition – supply side reform is the best way to describe it. And that’s not new in China; it happened in 2015. What triggered it back then was about 45 consecutive months of negative producer price index (PPI) growth. Fast forward to June 2025 when this thematic started to make noise – we’d had 33 consecutive months of negative PPI. A similar situation.

The difference from 2015 is that back then the supply side reform was joined with demand side stimulus, which led to a huge bull market in Chinese equities. So far we’ve had the supply side reform but haven’t really had effective demand side stimulus, and we’re not expecting significant demand side stimulus either. Initially, anti-involution led to a whole range of low-quality companies rallying on the expectation that profitability would go up, but without the demand side stimulus it will be hard for those companies to consistently perform.

The way we’ve benefited from this anti-involution thematic is through a company called CATL. We’ve looked for companies that, through the period of excessive competition, have generated strong returns on their own. CATL has seen its return on equity (ROE) increase every period through that excessive competition period, and their market share has gone up –they now have 40% market share in electric vehicle batteries and energy storage system batteries globally, making them the largest player in the world. Even in light of the US trying to shut China out. This company’s growth should actually accelerate now that the government is forcing lower quality players to pull back their expenditure and excessive competition. CATL is growing at circa 23–25% over the next 3 years and we’re able to buy that at 19 times price-to-earnings (PE). We see that as a really strong pragmatic value opportunity.

Another key structural theme we’ve invested in through the China Fund is China’s renewable energy transition. As most people broadly know, China is now the largest producer and the largest deployer of new renewables, and it’s doing so not only to achieve net zero but because renewables are now cheaper than traditional energy sources. We’re playing this in the portfolio from both a hardware and software perspective. Can you walk the audience through that?

China now has about 40% of its power generation coming from renewable sources. That’s helping reduce the cost of power production, which is really important both from a manufacturing and export perspective, as exports have been a key driver of GDP growth for China and it maintains their competitiveness. And as investment in artificial intelligence (AI) data centres grows, power is the largest cost, so China’s power advantage gives them something to offset the disadvantage of having less powerful chips.

With the ongoing rollout of renewables, you need to continue to build out the grid. China already has one of the most built-out grids in the world – they’ve been investing here for many decades – but as you add renewables, that buildout must continue. This is one of the key ways we’ve been investing to benefit from the renewables push in China.

Our main investments are in suppliers into the ultra-high voltage (UHV) line buildout – specifically XD and Pinggao. Both stocks have seen significant growth in their revenue and we expect that to continue over the next 5 years. They build primary equipment for the UHV line buildouts. We’ve also invested in Sieyuan which supplies equipment into China but also sells transformers and switchgear globally.

That’s a really interesting market because investment in the grid in the US – from a very low base – is essentially absorbing all the transformer and switchgear supply from the rest of the world. Chinese companies are generally not selling directly into the US, but they are selling into the rest of the world and benefiting from that tightness. Sieyuan is seeing extremely high levels of growth in their export business, and we think that continues for the foreseeable future, making these stocks really interesting growth opportunities within this thematic.

 

Overall, we have generated strong returns within the Antipodes China Fund above both global and Australian equities. We are expecting to see a broadening of those returns over time given the concentration we saw last year. There are many themes we are exposed to, including the anti-involution trade as well as structural themes like the upgrade of China’s grid and the ongoing deployment of renewable energy. There’s always a lot happening in China.

 

If you have any further questions, please reach out to your Antipodes representative or your representative from Pinnacle Investment Management.

Subscribe to receive the latest news and insights from the Antipodes team

IMPORTANT INFORMATION:
This information has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) as the Investment manager of the Antipodes China Fund (ARSN 116 380 771) (‘Fund’) and the Antipodes Asia Fund (ARSN 134 226 029) (‘Fund’). Maple-Brown Abbott Limited (“MBAL”) (ABN 73 001 208 564, AFSL 237296), is the Responsible Entity for the Antipodes China and Asia Funds. MBAL is a subsidiary of Antipodes Partners Holdings PTY LTD (ABN 91 602 828 526). This report contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent financial advice. This document does not constitute an offer or solicitation by anyone in any jurisdiction. Past performance is not a reliable indicator of future performance. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment.
Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Individual stocks referred to may or may not be currently held by the Fund. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS and Target Market Determination (TMD) or any other relevant disclosure document. For the Fund, the PDS, AIB and TMD are available at www.antipodes.com or by calling 1300 097 995.

Share:

More Posts

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X